Antibody-Coding RNA for Sustained In Vivo Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating tumors and cancer diseases, cardiovascular diseases, infectious diseases, and autoimmune diseases often rely on invasive therapies like chemotherapy, which burden the immune system and come with risks such as immune reactions and genetic mutations when using DNA-based gene therapy or vaccination.
Innovation Solution
The use of antibody-coding RNA molecules for intracellular expression, which can encode for various antibodies, including monoclonal, humanized, or bispecific antibodies, to provide therapeutic antibodies in vivo without the risks associated with DNA-based methods, such as immune reactions and genetic mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If DNA-based gene therapy or vaccination is used to deliver therapeutic antibodies in vivo, then sustained antibody production is achieved, but immune reactions and genetic mutations occur as harmful side effects
Solution Approach 1:
The patent changes the molecular parameter from DNA to RNA as the genetic material for antibody expression. RNA-based expression achieves sustained antibody production while avoiding the harmful effects of DNA-based approaches, including immune reactions to foreign DNA and risk of genomic integration mutations. The RNA is delivered with appropriate modifications and delivery mechanisms to ensure stability and sustained expression without the dangers associated with DNA.
2Productivity
If conventional chemotherapy or radiotherapy is used to treat tumors and cancer diseases, then tumor cells are destroyed, but the immune system is burdened and requires long regeneration pauses
Solution Approach 1:
The patent employs the patient's own immune system to produce therapeutic antibodies against tumor cells. By delivering RNA that encodes tumor-targeting antibodies, the body's cellular machinery is harnessed to continuously produce the therapeutic agent. This self-service approach eliminates the need for external chemotherapy agents that burden the immune system, as the immune system itself becomes the production facility for targeted therapy.
3Reliability
If invasive therapies like chemotherapy are used to treat diseases, then treatment effectiveness is achieved, but the treatment complexity and patient burden increase
Solution Approach 1:
The patent extracts the essential therapeutic function (antibody production) from complex conventional treatments and delivers it directly via RNA. Instead of using multi-step chemotherapy protocols or invasive procedures, the invention delivers only the necessary genetic information for antibody synthesis, allowing the patient's cells to produce the therapeutic agent autonomously. This simplifies the treatment from complex invasive procedures to a single targeted RNA delivery step.
Data Source
AI summary
The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.